Department of Anesthesiology; Yale School of Medicine; New Haven, CT, USA.
Yale Center for Analytical Sciences; New Haven, CT, USA.
J Clin Anesth. 2022 Sep;80:110846. doi: 10.1016/j.jclinane.2022.110846. Epub 2022 Apr 27.
We aimed to study the association between propofol induction dose (mg/kg) and pre-incision severe hypotension (Mean Arterial Pressure (MAP) ≤ 55 mmHg) among patients ≥65 years of age.
Retrospective Observational.
40 centers participating in the Multicenter Perioperative Outcomes Group consortium.
Patients ≥65 years of age undergoing non-cardiac, non-vascular surgery who received propofol for general anesthetic induction prior to endotracheal intubation between January 2014 and December 2018.
None.
The primary exposure was total propofol induction dose in mg/kg, and the primary outcome was occurrence of severe hypotension (MAP≤55 mmHg) prior to surgical incision, stratified by non-invasive vs. invasive blood pressure monitoring type.
Among 320,585 total patients, 22.6% experienced the outcome of pre-incision severe hypotension (MAP≤55 mmHg). When stratified by blood pressure monitoring type, 20.7% with non-invasive blood pressure measurements, and 35.0% with invasive blood pressure measurements had the outcome. After controlling for a variety of patient and procedural factors, there was a significant independent association between propofol induction dose and pre-incision hypotension (Non-invasive blood pressure cohort odds ratio (OR) 1.10; 95% confidence interval (CI) 1.07 to 1.13; p < 0.001; and Invasive blood pressure cohort OR 1.15; 95%CI 1.10 to 1.21; adjusted p < 0.001). The association was robust to alternative definitions of the outcome, including less severe hypotension (MAP≤65 mmHg) and blood pressure drop from baseline as a continuous measure. Although no threshold safe induction dose was identified at which hypotension was avoided, an analysis of propofol dose greater or less than 1.5 mg/kg (i.e. the maximum FDA-defined typical induction dose) demonstrated that doses in excess of the FDAs threshold were positively associated with odds of severe hypotension (Non-invasive cohort: OR 1.05; 95% CI 1.02 to 1.08; p < 0.001; Invasive cohort: OR 1.11; 95%CI 1.05 to 1.17; adjusted p < 0.001).
In a multicenter cohort of geriatric surgical patients receiving propofol for general anesthetic induction and endotracheal intubation, severe pre-incision hypotension (MAP ≤55 mmHg) that has previously been associated with postoperative morbidity was common. The dose of propofol used was significantly associated with increased odds of this outcome after controlling for a number of clinically relevant factors. Future studies that are designed to test different approaches to anesthesia induction for reducing severe post induction pre-incision hypotension are warranted.
我们旨在研究 65 岁以上患者中异丙酚诱导剂量(mg/kg)与术前严重低血压(平均动脉压(MAP)≤55mmHg)之间的关系。
回顾性观察。
参加多中心围手术期结局组联盟的 40 个中心。
65 岁以上接受非心脏、非血管手术的患者,在 2014 年 1 月至 2018 年 12 月期间,在气管内插管前接受异丙酚全身麻醉诱导。
无。
主要暴露是总异丙酚诱导剂量(mg/kg),主要结局是手术切口前发生严重低血压(MAP≤55mmHg),按非侵入性与侵入性血压监测类型分层。
在 320585 名总患者中,22.6%发生术前严重低血压(MAP≤55mmHg)。按血压监测类型分层,20.7%接受非侵入性血压测量,35.0%接受侵入性血压测量。在控制各种患者和手术因素后,异丙酚诱导剂量与术前低血压之间存在显著的独立关联(非侵入性血压测量队列优势比(OR)1.10;95%置信区间(CI)1.07 至 1.13;p<0.001;和侵入性血压测量队列 OR 1.15;95%CI 1.10 至 1.21;调整后 p<0.001)。该关联对替代结局定义具有稳健性,包括不那么严重的低血压(MAP≤65mmHg)和作为连续测量的血压下降。虽然没有确定避免低血压的安全诱导剂量阈值,但对 1.5mg/kg 以上或以下(即 FDA 定义的最大典型诱导剂量)的异丙酚剂量进行分析表明,超过 FDA 阈值的剂量与严重低血压的几率呈正相关(非侵入性队列:OR 1.05;95%CI 1.02 至 1.08;p<0.001;侵入性队列:OR 1.11;95%CI 1.05 至 1.17;调整后 p<0.001)。
在接受异丙酚全身麻醉诱导和气管内插管的老年外科患者多中心队列中,先前与术后发病率相关的严重术前低血压(MAP≤55mmHg)很常见。在控制了许多临床相关因素后,异丙酚的剂量与该结局的几率增加显著相关。需要进行旨在测试不同麻醉诱导方法以减少严重诱导后术前低血压的研究。